BIOMARIN PHARMACEUTICAL INC (BMRN) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 3.41B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $3.41B | (m) | (m) |
| 2026-03-31 | (m) | $3.24B | (m) | (m) |
| 2025-12-31 | (m) | $3.22B | (m) | (m) |
| 2025-09-30 | (m) | $3.09B | (m) | (m) |
| 2025-06-30 | (m) | $3.06B | (m) | (m) |
| 2025-03-31 | (m) | $2.95B | (m) | (m) |
| 2024-12-31 | (m) | $2.85B | (m) | (m) |
| 2024-09-30 | (m) | $2.75B | (m) | (m) |
| 2024-06-30 | (m) | $2.59B | (m) | (m) |
| 2024-03-31 | (m) | $2.47B | (m) | (m) |
| 2023-12-31 | (m) | $2.42B | (m) | (m) |
| 2023-09-30 | (m) | $2.31B | (m) | (m) |
| 2023-06-30 | (m) | $2.23B | (m) | (m) |
| 2023-03-31 | (m) | $2.17B | (m) | (m) |
| 2022-12-31 | (m) | $2.10B | (m) | (m) |
| 2022-09-30 | (m) | $2.01B | (m) | (m) |
| 2022-06-30 | (m) | $1.91B | (m) | (m) |
| 2022-03-31 | (m) | $1.88B | (m) | (m) |
| 2021-12-31 | (m) | $1.85B | (m) | (m) |
| 2021-09-30 | (m) | $1.85B | (m) | (m) |
| 2021-06-30 | (m) | $1.92B | (m) | (m) |
| 2021-03-31 | (m) | $1.84B | (m) | (m) |
| 2020-12-31 | (m) | $1.86B | (m) | (m) |
| 2020-09-30 | (m) | $1.86B | (m) | (m) |
| 2020-06-30 | (m) | $1.85B | (m) | (m) |
| 2020-03-31 | (m) | $1.81B | (m) | (m) |
| 2019-12-31 | (m) | $1.70B | (m) | (m) |
| 2019-09-30 | (m) | $1.60B | (m) | (m) |
| 2019-06-30 | (m) | $1.53B | (m) | (m) |
| 2019-03-31 | (m) | $1.52B | (m) | (m) |
| 2018-12-31 | (m) | $1.49B | (m) | (m) |
| 2018-09-30 | (m) | $1.50B | (m) | (m) |
| 2018-06-30 | (m) | $1.44B | (m) | (m) |
| 2018-03-31 | (m) | $1.38B | (m) | (m) |
| 2017-12-31 | (m) | $1.31B | (m) | (m) |
| 2017-09-30 | (m) | $1.26B | (m) | (m) |
| 2017-06-30 | (m) | $1.20B | (m) | (m) |
| 2017-03-31 | (m) | $1.18B | (m) | (m) |
| 2016-12-31 | (m) | $1.12B | (m) | (m) |
| 2016-09-30 | (m) | $1.04B | (m) | (m) |
| 2016-06-30 | (m) | $973.71M | (m) | (m) |
| 2016-03-31 | (m) | $923.71M | (m) | (m) |
| 2015-12-31 | (m) | $889.89M | (m) | (m) |
| 2015-09-30 | (m) | $893.78M | (m) | (m) |
| 2015-06-30 | (m) | $861.49M | (m) | (m) |
| 2015-03-31 | (m) | $802.75M | (m) | (m) |
| 2014-12-31 | (m) | $751.04M | (m) | (m) |
| 2014-09-30 | (m) | $667.06M | (m) | (m) |
| 2014-06-30 | (m) | $627.09M | (m) | (m) |
| 2014-03-31 | (m) | $572.11M | (m) | (m) |
| 2013-12-31 | (m) | $548.49M | (m) | (m) |
| 2013-09-30 | (m) | $533.55M | (m) | (m) |
| 2013-06-30 | (m) | $524.79M | (m) | (m) |
| 2013-03-31 | (m) | $512.00M | (m) | (m) |
| 2012-12-31 | (m) | $500.72M | (m) | (m) |
| 2012-09-30 | (m) | $476.63M | (m) | (m) |
| 2012-06-30 | (m) | $461.94M | (m) | (m) |
| 2012-03-31 | (m) | $448.55M | (m) | (m) |
| 2011-12-31 | (m) | $441.36M | (m) | (m) |
| 2011-09-30 | (m) | $435.13M | (m) | (m) |
| 2011-06-30 | (m) | $419.45M | (m) | (m) |
| 2011-03-31 | (m) | $400.77M | (m) | (m) |
| 2010-12-31 | (m) | $376.27M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $324.66M | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $296.49M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |